 |
 |
 |
||
 |
March 31, 2010 |  |
||
 |
 |
|||
 Paul Wolpe, PhD |
|
|||
|
|
|||
|
Decades of Fragile X Research Lead to Testing of Targeted Treatment Emory scientists have been research leaders in fragile X syndrome—the most common inherited cause of intellectual disability. Geneticist Steve Warren headed the 1991 team that identified the mutated gene on the X chromosome, and he has continued making new discoveries. Now a possible treatment is in sight, and Emory is part of a clinical trial testing targeted drug therapy. Read more... |
|||
|
|
|||
Chymase-producing cells in the human heart (shown in pink) |
Chymase Inhibitors Could Boost Treatment for Damaged Hearts Millions of patients with high blood pressure and heart failure take ACE inhibitors to prevent the body from processing angiotensin II, a hormone that constricts blood vessels. Now scientists think blocking another heart enzyme called chymase may enhance the effects of ACE inhibitors after heart attack. Read more... |
|||
|
|
|||
 |
Are Obesity and Metabolic Disease Contagious? It's often assumed the obesity epidemic is driven by high-calorie foods, a sedentary lifestyle, and undisciplined eating; however, intestinal bacteria also may contribute to changes in appetite and metabolism. Populations of intestinal bacteria differ between obese and lean humans, and in the lab, these bacteria can transfer increased appetite and insulin resistance from mouse to mouse. Read more... |
|||
|
|
|||
Gang Bao, PhD |
New National Science Foundation Center Advances Cell Systems Research Georgia Tech and Emory biomedical engineers will partner with MIT and the University of Illinois through a $25 million NSF grant for the Emergent Behaviors of Integrated Cellular Systems Center. EBICS will focus on complex biological systems, create new educational programs, and involve under-represented groups in science and engineering. Read more... |
|||
 |
 |
|||
